[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:perivascular-inflammation":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":24,"states":25},"Perivascular inflammation",2,1,[8,16],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07219043","A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation",[12],"Phase 2","RECRUITING","2026-08-26T02:18:19.586423Z","2026-05-05T02:35:31.708141Z",{"nct_id":17,"title":18,"phases":19,"status":21,"updated_at":22,"content_modified":23},"NCT07444489","A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND\u002FTRANSPIRE LTE)",[20],"Phase 3","ENROLLING_BY_INVITATION","2026-08-26T02:16:03.788292Z","2026-07-05T05:32:16.681628Z",[],[]]